AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureInformation ScienceNamed GroupsHealth Care
Bone Marrow TransplantationBone MarrowBone Marrow CellsTransplantation, HomologousGraft vs Host DiseaseHistocompatibilityBone and BonesHematopoietic Stem Cell TransplantationLeukemiaTissue DonorsHistocompatibility TestingTransplantation ConditioningWhole-Body IrradiationHematologic NeoplasmsGraft SurvivalTransplantation ChimeraAnemia, AplasticTransplantation, AutologousHLA AntigensSevere Combined ImmunodeficiencyLymphocyte DepletionCytomegalovirus InfectionsImmunosuppressive AgentsHematopoietic Stem CellsLeukemia, Myeloid, AcuteBone RemodelingHaploidyTreatment OutcomeBone Marrow DiseasesBone Marrow ExaminationGraft RejectionRecurrencePrecursor Cell Lymphoblastic Leukemia-LymphomaBone Marrow PurgingImmunocompromised HostT-LymphocytesBone Marrow NeoplasmsOpportunistic InfectionsTime FactorsLymphocyte TransfusionHaplotypesImmunosuppressionLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHematopoiesisPeripheral Blood Stem Cell TransplantationMice, Inbred C57BLCyclosporineAcute DiseaseRetrospective StudiesBone DensityAntilymphocyte SerumMycosesCyclophosphamideGraft vs Leukemia EffectKidney TransplantationFetal TherapiesRadiation ChimeraCytomegalovirusBusulfanAntigens, CD34Fatal OutcomeBone ResorptionLiving DonorsTransplantation, IsogeneicColony-Forming Units AssayHematologic DiseasesPneumonia, ViralRemission InductionUnrelated DonorsNuclear FamilyDisease-Free SurvivalSiblingsGanciclovirSurvival AnalysisCord Blood Stem Cell TransplantationStem Cell TransplantationCombined Modality TherapyGraft vs Host ReactionAspergillosisMyelodysplastic SyndromesSurvival RateLeukemia, MyeloidCell DifferentiationBone NeoplasmsFollow-Up StudiesCystitisHepatic Veno-Occlusive DiseaseReceptors, KIRGranulocyte Colony-Stimulating FactorBlood Group IncompatibilityPolymerase Chain ReactionTransplantsMucormycosisLymphoma, Non-HodgkinKiller Cells, NaturalFlow CytometryCells, CulturedBone DevelopmentLeukocyte CountMyeloablative Agonists
TransplantationOutcomesCyclophosphamideAutologousGraft-versus-DonorsBiol Blood Marrow TransplantUmbilicalHematopoietic stem cell transpConditioning regimensAllogeneic hematopoietic sPatientsBiopsyCIBMTRStem cell transplantsMortalityPeripheral blood stemAcute MyeloidMyeloablativePost-transplant relapseRelapseCellsRegimenCell TherHuman leukocyAspirationImmuneClinicalProcedureBiopsiesRepleteChemotherapy and radiationRemissionHSCT2017Type of transplantPatient'sInfections
Transplantation31
  • During the last few years, the therapeutic landscape of idiopathic aplastic anemia (IAA) has been profoundly revolutionized by the increased use of alternative transplant procedures, such that today hematopoietic cell transplantation (HCT) from a matched unrelated donor (MUD) has been suggested as a possible first line strategy in pediatric patients with severe IAA, in the absence of a matched related donor. (bvsalud.org)
  • Objective: To evaluate the efficacy and safety of HLA-haploidentical hematopoietic stem cell transplantation (allo-HSCT) for hepatitis-related aplastic anemia (HRAA) patients. (bvsalud.org)
  • Slavin pioneered the use of immunotherapy mediated by allogeneic donor lymphocytes and innovative methods for stem cell transplantation for the cure of hematological malignancies and solid tumors, and using hematopoietic stem cells for induction of transplantation tolerance to bone marrow and donor allografts. (wikipedia.org)
  • In 1975-1978, Slavin trained in clinical immunology/rheumatology at the Division of Immunology, Stanford University School of Medicine and later on in 1978, trained in clinical bone marrow transplantation under the late E.D. Thomas at the Fred Hutchinson Cancer Research Center in Seattle, Washington. (wikipedia.org)
  • Upon returning to Jerusalem, he opened the first Bone Marrow Transplantation Center at the Hadassah University Hospital, which was later recognized as Israel's National Bone Marrow Transplantation and & Cancer Immunotherapy Center. (wikipedia.org)
  • As such, innovative reduced intensity conditioning (RIC) or non-myeloablative stem cell transplantation (NST) was pioneered by Slavin for safer stem cell transplantation for the treatment of malignant and life-threatening non-malignant disorders correctable by using stem cells and post-transplant immunotherapy if indicated for all patients in need. (wikipedia.org)
  • Retrospective analysis by the Center for International Blood and Marrow Transplant Research (CIBMTR): Prompt complete remission plus consolidation therapy yields improved survival after allogeneic hematopoietic cell transplantation (allo-HCT) for patients with acute myeloid leukemia (AML) receiving a myeloablative conditioning regimen and not a reduced-intensity conditioning regimen. (ascopost.com)
  • Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. (uchicago.edu)
  • Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • 2020 was an important year for Gamida Cell as we made significant progress across our entire pipeline, including omidubicel, which is poised to become the first FDA approved cell therapy for bone marrow transplantation. (seekingalpha.com)
  • Bone marrow transplantation is a complex yet life-saving procedure that can benefit individuals with a wide range of diseases, including blood cancers like leukemia and lymphoma, aplastic anemia, immune deficiencies, and genetic disorders. (yapitahealth.com)
  • Recipients of allogeneic transplantation had significantly improved overall survival compared to non-transplanted patients. (oncotarget.com)
  • Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. (mcw.edu)
  • Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. (mcw.edu)
  • Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. (mcw.edu)
  • HLA-haploidentical TCRalphabeta+/CD19+-depleted stem cell transplantation in children and young adults with Fanconi anemia. (gitmo.it)
  • Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Children and Adolescents with Fanconi Anemia. (gitmo.it)
  • Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. (gitmo.it)
  • Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. (gitmo.it)
  • Dr. Al Malki is an Associate Professor in the Department of Hematology & Hematopoietic Cell Transplantation and Director of the Unrelated Donor Bone Marrow Transplant and Haploidentical Transplant Programs at City of Hope. (tscan.com)
  • Heme Malignancies Program: TScan's two lead TCR-T cell therapy candidates, TSC-100 and TSC-101, are designed to target HA-1 and HA-2, respectively, to treat residual disease and prevent relapse in acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myelodysplastic syndromes (MDS) patients undergoing allogeneic haploidentical hematopoietic cell transplantation (HCT) with reduced intensity conditioning (RIC). (tscan.com)
  • RECENT FINDINGS: Stem cell sources, novel transplant methods, and sophisticated supportive care have simultaneously made giant strides toward improving the safety and efficacy of hematopoietic cell transplantation. (wustl.edu)
  • Dr. George Mathé explored the transplantation of bone marrow cells from healthy donors to treat patients accidentally irradiated at high dose, expanding the possibilities of this life-saving technique (Mathé et al. (revistadehematologia.org.mx)
  • Under the slogan of "cure without late complications," we have successfully minimized treatment-related late complications with reduced intensity conditioning (RIC) for hematopoietic stem cell transplantation and immunotherapy, which have smaller side effects. (opho.jp)
  • We perform all types of hematopoietic stem cell transplantation (HSCT) including bone marrow transplantation, peripheral blood stem cell transplantation, and umbilical cord blood transplantation. (opho.jp)
  • Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. (wustl.edu)
  • And she's also an associated editor for the medical journal Bone Marrow Transplantation as well as a protocol officer and medical monitor for the National Heart Lung and Blood Institute, National Cancer Institute, Blood & Marrow Transplant Clinical Trials Network. (bmtinfonet.org)
  • This is a Phase II study for the use of T-cell replete reduced intensity conditioning (RIC) haploidentical donor allogeneic hematopoietic cell transplantation (HaploHCT) for individuals with high-risk non-malignant diseases who lack a suitable HLA-matched sibling donor. (umn.edu)
  • The Allogeneic bone-marrow transplantation represents the only curative treatment and requires a compatible donor HLA. (longdom.org)
  • Allogeneic bone marrow transplantation, as we understood it, allows saving lives, but cannot take place without donors. (longdom.org)
  • If the geno-identical transplantation is impossible, we will direct ourselves towards the national and international register donors of bone marrow. (longdom.org)
Outcomes13
  • Mayo Clinic scientists are actively studying ways to improve bone marrow transplant outcomes. (mayoclinic.org)
  • However, in this particular context, outcomes and early and long-term toxicities remain to be determined, as compared to non-transplant procedures. (bvsalud.org)
  • We compared outcomes of HSCT from HLA-identical (HLA-id, n = 1654) sibling or haploidentical (Haplo, n = 389) donors in patients with R/R-AML, performed during the period 2007-2015. (unisr.it)
  • An important and unanswered question concerns the impact of the number of conventional AML chemotherapy induction cycles to achieve first complete remission on transplant outcomes. (ascopost.com)
  • Similarly, the outcomes of myeloablative conditioning and reduced-intensity conditioning regimens for allo-HCT and their relationship with pretransplant consolidation cycles for patients in first complete remission are also unknown. (ascopost.com)
  • This large retrospective analysis on behalf of the CIBMTR shows again that among patients eligible for allo-HCT, only one induction cycle to achieve first complete remis sion, particularly when combined with one consolidation therapy, is associated with better outcomes after myeloablative conditioning and not reduced-intensity conditioning. (ascopost.com)
  • Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients. (mcw.edu)
  • The ultimate goal is to provide curative transplant options for more patients that can benefit from this intervention, prior to detrimental outcomes. (wustl.edu)
  • 12 months = 0) was generated as an approach to classify patients into different risk categories in the purpose to provide guidance to the transplant physician to inform the outcomes to potential patients undergoing 2nd HCT. (biomedcentral.com)
  • 00:06:54): The goal of interventional clinical trials is to improve transplant outcomes through a scientific rationale. (bmtinfonet.org)
  • The standard treatment is blood stem cell transplant, but outcomes are dependent on finding the disease early. (umn.edu)
  • In this month's Pharmacy SIG Literature Update: Impact of anti-T-lymphocyte globulin dosing on GVHD in MUD SCT, impact of MRD status before alloHCT on outcomes in secondary AML, low-dose post- transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of GVHD in MUD SCT and more. (astct.org)
  • Neither pre-transplant clinical characteristics nor transplant characteristics are reliably predictive of GvHD outcomes. (cryostem.org)
Cyclophosphamide2
  • Low-dose post-transplant cyclophosphamide (PTCy) in conjunction with anti-thymocyte globulin (ATG) appears as a potentially effective graft-versus-host disease (GVHD) prevention strategy in haploidentical hematopoietic cell transplant (haplo-HCT). (biomedcentral.com)
  • In addition, we perform HLA-haploidentical HSCT, including HCT with post-transplant cyclophosphamide (PTCY) for non/less-malignant hematological diseases, and T-cell replete HSCT for advanced leukemia. (opho.jp)
Autologous9
  • While prospective trials are ongoing, we report here the case of a 12-year-old boy with IAA, receiving an upfront bone marrow HCT from a MUD, who experienced early graft rejection associated with autologous hematological recovery, which could induce remission of his hemopathy. (bvsalud.org)
  • This case offers the opportunity to discuss the challenges associated with these new transplant paradigms and provides a brief review of the literature regarding the issue of autologous recoveries after allogeneic HCT in IAA. (bvsalud.org)
  • Autologous bone marrow transplant -- The term auto means self. (medlineplus.gov)
  • Transplant of haematopoietic progenitors (autologous, allogeneic relatives and unrelated donors). (vallhebron.com)
  • Finding accommodation in a hotel because patients for autologous transplants need to stay for 30 days locally and allogenic transplant patients need to stay for 100 days. (yapitahealth.com)
  • In autologous transplant- the patient's own stem cells are collected and stored before conditioning. (yapitahealth.com)
  • Allogeneic HCT has been widely used, while autologous HCT, which is still useful, is less prevalent because of concerns around post-transplant relapse, as well as the recently extended application of allogeneic HCT. (apbmt.org)
  • Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. (astct.org)
  • In recent years, especially after the advent of reduced intensity conditioning in the late 1990s, allogeneic HSCT is increasingly used in older patients and as an effective salvage strategy for patients with lymphoma or myeloma not responding to chemotherapy or autologous HSCT. (longdom.org)
Graft-versus-4
  • Acute Graft-versus-host disease (GvHD), one of the major complications of HSCT, is correlated to conditioning-induced gut barrier damage and may be predicted by pre-transplant serum citrulline level (Rashidi, BBMT 2018). (confex.com)
  • The side effects of this type of transplant include increased risk of infections, excessive bleeding, graft-versus-host disease, etc. (bgsgleneaglesglobalhospitalbengaluru.com)
  • Data on the impact of chronic Graft-versus-host disease (cGvHD) on cognitive function (CF) and quality of life (QoL) of long-term transplant survivors are sparse. (biomedcentral.com)
  • Transplant complications such as graft rejection, infections, and graft versus host disease are better combated in this modern era of medicine, achieving better survival with decreased late effects. (wustl.edu)
Donors4
  • Donors who are not related to you, yet still match, may be found through national bone marrow registries. (medlineplus.gov)
  • Donors were HLA-matched related (n = 4), HLA-matched unrelated (n = 16), HLA-haploidentical (n = 2), or HLA-mismatched unrelated (n = 8). (cardiff.ac.uk)
  • Donors included matched sibling donors (MSD), matched unrelated donors (MUD), mismatched unrelated donors (MMUD) and haploidentical/mismatched related donors (MMRD). (biomedcentral.com)
  • Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type. (mcw.edu)
Biol Blood Marrow Transplant1
Umbilical3
  • Umbilical cord blood transplant -- This is a type of allogeneic transplant. (medlineplus.gov)
  • Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. (uchicago.edu)
  • Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. (uchicago.edu)
Hematopoietic stem cell transp1
  • In immunocompromised populations, such as patients with AIDS and recipients of solid organ and hematopoietic stem cell transplants, BK polyomavirus (BKPyV) can reactivate and cause several diseases, which can lead to death in their severe forms. (biomedcentral.com)
Conditioning regimens3
  • The conditioning regimens for the final transplants were myeloablative (n = 20), reduced intensity (n = 8), or non-myeloablative (n = 2). (cardiff.ac.uk)
  • This has led to the utilization of marrow, cord, peripheral blood stem cell and haploidentical stem cell sources, and novel reduced toxicity or reduced intensity conditioning regimens to transplant non-malignant disorders such as immune dysfunctions, marrow failure syndromes, metabolic disorders and hemoglobinopathies. (wustl.edu)
  • This single-institution, phase II study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe osteopetrosis (OP). (umn.edu)
Allogeneic hematopoietic s2
  • The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care. (mayo.edu)
  • Second allogeneic hematopoietic stem cell transplant (HCT) remains as an option for disease relapse after initial HCT. (biomedcentral.com)
Patients19
  • Bone marrow involvement is more common in elderly patients and those with advanced-stage disease, systemic symptoms, or a high-risk histology. (medscape.com)
  • Among 161 patients (pts) included in the study, with a median age of 53 years (17-72), 98 pts (60.9%) received a reduced-intensity conditioning (RIC), 36 pts (22.4%) reduced-toxicity conditioning (RTC), 18 pts (11.1 %) sequential conditioning, and 9 pts (5.6%) myeloablative conditioning (MAC). (confex.com)
  • This is an option for patients who can't endure a full-intensity or myeloablative allogeneic transplant. (bgsgleneaglesglobalhospitalbengaluru.com)
  • Adult patients (age ≥ 18) eligible for and planned to undergo a standard-of-care reduced intensity conditioning (RIC) HLA-matched related or related haploidentical allogeneic stem cell transplant using PTCY-based GVHD prophylaxis. (survivornet.com)
  • A total of 1,473 patients with a median age of 47 years received myeloablative conditioning, and 1,162 patients with a median age of 63 years received reduced-intensity conditioning. (ascopost.com)
  • About 328 patients received myeloablative conditioning, and 150 patients, reduced-intensity conditioning. (ascopost.com)
  • 01). Treatment-related mortality was similar for patients with primary induction failure vs those in first complete remission after myeloablative or reduced-intensity conditioning allo-HCT (Table 1). (ascopost.com)
  • Patients completed the Functional Assessment of Cancer Therapy-Bone marrow transplant (FACT-BMT, version 4), the FACT-Cognition Function (FACT-Cog, version 3), the Patient Health Questionaire-4 (PHQ-4) and a questionnaire about sociodemographic data. (biomedcentral.com)
  • This global trial evaluated omidubicel versus standard cord blood in patients with hematologic malignancies, who needed a bone marrow transplant, but did not have a suitable match donor. (seekingalpha.com)
  • Patients are explained thoroughly regarding Bone marrow transplant including the evaluation process, treatment side effects, cost of treatment, and associated complications. (yapitahealth.com)
  • Before transplant patients are instructed to stay away from sick people. (yapitahealth.com)
  • The clinical presentation of patients with aplastic anemia includes signs and symptoms related to the decrease in bone marrow production of hematopoietic cells. (medscape.com)
  • In all patients that might become considered for intensive treatment, the AML diagnosis should be based on morphologic and immunophenotypic features of bone marrow aspirates as well as on genetic characteristics of the leukemic blasts. (cancercentrum.se)
  • A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML (BMT CTN 1506) Rochester, Minn., Scottsdale/Phoenix, Ariz. (mayo.edu)
  • The 5-year probability of overall survival (OS) after allogeneic HCT was estimated to be 56% (95% confidence interval[CI], 55%- 57%) for patients receiving a transplant while in CR, and 22% (95% CI, 21%-23%) for those who were experiencing active disease. (apbmt.org)
  • Clinical trials for stem cell and bone marrow transplant patients are an important tool for identifying new and more effective treatments for many diseases. (bmtinfonet.org)
  • Clinical Trials are something that are frequently done for all types of cancer patients and we're going to focus a little bit more on how this works for patients going through transplants specifically. (bmtinfonet.org)
  • This trial confirmed the results of other trials that demonstrated a substantial incidence of symptomatic hypotension in MM patients in the peri-transplant period following ASCT. (astct.org)
  • In a combined analysis of categorical groups, the patients in the high A- ALC group transplanted in CR1 had the best prognosis for OS and PFS and patients in the low A- ALC group transplanted in CR/PR after second-line therapy had the worse prognosis for OS and PFS. (astct.org)
Biopsy2
  • Bone marrow biopsy is performed in addition to aspiration to assess cellularity qualitatively and quantitatively. (medscape.com)
  • A bone marrow aspirate and biopsy provide no specific diagnostic information because these may be normal or indistinguishable from ET or PMF. (basicmedicalkey.com)
CIBMTR1
  • She serves as a scientific director for the Center for International Blood & Marrow Transplant Research or CIBMTR, under their infection and immune reconstitution committee. (bmtinfonet.org)
Stem cell transplants2
Mortality3
  • We theorized that lower Treatment Related Mortality (TRM) with Reduced Intensity Conditioning (RIC) would bring about better Overall Survival (OS) contrasted and Myelo ablative Conditioning (MAC). (scitechnol.com)
  • 1980). As with many countries embarking on this procedure, there were challenges related to transplant-related morbidity and mortality. (revistadehematologia.org.mx)
  • Transplant-related mortality (TRM), although steadily declining, still remains a challenge [ 2 ]. (longdom.org)
Peripheral blood stem1
  • The number of related HCTs has remained stable, while the use of peripheral blood stem cells (PBSCs) has now largely replaced that of bone marrow (BM). (apbmt.org)
Acute Myeloid4
  • The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS and myeloproliferative neoplasm (MPN) overlap syndrome after a standard-of-care stem cell transplant. (survivornet.com)
  • This is a phase I/Ib study of the pre-emptive treatment using related donor-derived cytokine induced memory-like (CIML) natural killer (NK) cells combined with Interleukin-2 (IL-2) for participants with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and MDS/myeloproliferative neoplasm (MDS/MPN) overlap syndrome at high risk for post-allogeneic stem cell transplant (SCT) relapse. (survivornet.com)
  • Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia. (mcw.edu)
  • DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. (mcw.edu)
Myeloablative1
  • Mini transplant or reduced-intensity therapy means chemotherapy and radiation in smaller doses while myeloablative or ablative therapy means high doses of radiation, chemotherapy, or combination. (yapitahealth.com)
Post-transplant relapse1
  • Histologically or cytologically confirmed diagnosis of AML, MDS, or MDS/MPN that is at high risk for post-transplant relapse and that has measurable disease prior to transplant using MRD-depth next-generation duplex sequencing with error suppression. (survivornet.com)
Relapse2
  • The purpose of this study is to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period. (mayo.edu)
  • The treatment options for disease relapse after HCT include withdrawal of immune suppression, chemotherapy, second allogeneic transplant, cytokine and adoptive cell therapy and donor lymphocyte infusion [ 1 ]. (biomedcentral.com)
Cells25
Regimen3
  • 0.01) and with a reduced intensity conditioning regimen (50% vs 43%, p = 0.03). (unisr.it)
  • Reduced-Intensity Preparative Regimen for. (checkorphan.org)
  • In this study, we analyzed patient-reported CF and QoL focusing on long-term transplant survivors after 1st allo-HSCT applying a standardized TBI-technique as conditioning regimen. (biomedcentral.com)
Cell Ther1
Human leukocy1
  • It advocates the consideration of alternative donor transplants in the absence of human leukocyte antigen matched siblings when indicated by disease severity. (wustl.edu)
Aspiration2
  • Bone marrow aspiration is performed after hematopoietic recovery, or day 28 at the latest. (cancercentrum.se)
  • Bone marrow aspiration is carried out by a puncture on the level of the sternum or the posterior iliac peaks under local anesthesia by the doctor. (longdom.org)
Immune2
  • Purpose Deficiency of adenosine deaminase 2 (DADA2) is an inherited inborn error of immunity, characterized by autoinflammation (recurrent fever), vasculopathy (livedo racemosa, polyarteritis nodosa, lacunar ischemic strokes, and intracranial hemorrhages), immunodeficiency, lymphoproliferation, immune cytopenias, and bone marrow failure (BMF). (cardiff.ac.uk)
  • With damaged bone marrow, the body's immune system becomes weak and it increases the patient's risk of infections. (yapitahealth.com)
Clinical2
  • The clinical course of individuals with MF is heterogeneous and characterized by constitutional symptoms, bone marrow myeloproliferation and fibrosis, progressive cytopenias, and symptomatic splenomegaly. (cancernetwork.com)
  • The clinical course of individuals with MF is characterized by constitutional symptoms (fevers, night sweats, and weight loss), bone marrow myeloproliferation and reticulin/collagen fibrosis, worsening cytopenias, thrombosis, and progressive symptomatic splenomegaly. (cancernetwork.com)
Procedure2
Biopsies1
  • Bone marrow biopsies are indicated in some cases. (medscape.com)
Replete1
  • The number of T-cell replete HLA-haploidentical HSCT for advanced cases was 6. (opho.jp)
Chemotherapy and radiation2
  • Reduced intensity treatment, also called a mini transplant -- Lower doses of chemotherapy and radiation are given before a transplant. (medlineplus.gov)
  • A stem cell transplant is usually done after chemotherapy and radiation is complete. (medlineplus.gov)
Remission1
  • The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. (wustl.edu)
HSCT1
  • Of the 21 allogeneic HSCT in 2020, 20 were transplanted using RIC. (opho.jp)
20171
  • I received 6 rounds of chemotherapy followed by a stem cell transplant in January of 2017. (cancer.org)
Type of transplant1
  • Additionally, it is important to consider the cost of the transplant, as it can vary depending on various factors, such as the type of transplant and the hospital. (yapitahealth.com)
Patient's1
  • This patient's marrow stroma and lymphocytes showed a hypersensitivity to irradiation similar to that observed in PNP-deficient mice. (medilib.ir)
Infections1
  • External insults (eg, infections, radiation, drugs) may disrupt stem cell homeostasis in marrow environment, leading to altered growth. (medscape.com)